Company news

Lipocine Inc. news in 2024

Lipocine Inc.'s news releases, calls and decks from 2024, newest first.

View company

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

December 16, 2024

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

November 17, 2024

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

November 6, 2024

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

October 30, 2024

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

October 9, 2024

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

October 7, 2024

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

October 1, 2024

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

September 4, 2024

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

August 7, 2024

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

June 24, 2024

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

June 9, 2024

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 8, 2024

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 7, 2024

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

April 30, 2024

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

April 10, 2024

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

March 27, 2024

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

March 24, 2024

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

March 6, 2024

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

February 5, 2024

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

February 1, 2024

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

January 17, 2024

Decks in 2024